USPTO Examiner NICOL ALEXANDER W - Art Unit 1634

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18784317COMPOSITION FOR REGULATING PRODUCTION OF PROTEINSJuly 2024February 2025Allow610NoNo
18405995CRISPR/CAS9-BASED REPRESSORS FOR SILENCING GENE TARGETS IN VIVO AND METHODS OF USEJanuary 2024May 2025Allow1720YesNo
18375868LYMPHOCYTE TARGETED LENTIVIRAL VECTORSOctober 2023April 2024Allow720YesNo
18470189SMALL TYPE II-D CAS PROTEINS AND METHODS OF USE THEREOFSeptember 2023September 2024Allow1221YesNo
18359013HIGH-TRANSDUCING HSV VECTORSJuly 2023December 2024Allow1610NoNo
18344732HOMOLOGY DIRECTED REPAIR COMPOSITIONS FOR THE TREATMENT OF HEMOGLOBINOPATHIESJune 2023April 2025Allow2111YesNo
18138361TRIPLE FUNCTION ADENO-ASSOCIATED VIRUS (AAV)VECTORS FOR THE TREATMENT OF C9ORF72 ASSOCIATED DISEASESApril 2023June 2025Abandon2511NoNo
18052082OPTIMIZED CLN1 GENES AND EXPRESSION CASSETTES AND THEIR USENovember 2022November 2024Allow2510NoNo
17484479VAGINAL REJUVENATION METHODS AND DEVICESSeptember 2021January 2025Abandon3931YesNo
17339755METHOD AND DEVICE FOR DRUG SCREENINGJune 2021April 2025Abandon4621NoNo
17294031Materials and Methods for Pathologies in Muscle following Injury, Disease or AgingMay 2021November 2024Abandon4201NoNo
17195357METHOD OF PRODUCING CAR-T CELLS, NUCLEIC ACID-INTRODUCING CARRIER AND KITMarch 2021April 2025Allow5021YesNo
17271314In Vivo Genetic Engineering of Antigen Responsive CellsFebruary 2021May 2025Abandon5120NoNo
17180406METHODS FOR ASSESSING TRANSENDOTHELIAL BARRIER INTEGRITYFebruary 2021February 2025Abandon4811NoNo
17263435Heterorhabditis Bacteriophora with Enhanced Shelf-LifeJanuary 2021February 2025Allow4911NoNo
17262900METHOD FOR GENE TRANSFER INTO GAMMA-DELTA TYPE T CELLJanuary 2021June 2025Allow5331YesNo
17072591HETEROZYGOUS TRANSGENIC ANIMALOctober 2020April 2025Abandon5461YesNo
17045802Genetically Modified T-Cells and PI3K/AKT Inhibitors For Cancer TreatmentOctober 2020November 2024Abandon4911NoNo
16962005CLOSED-ENDED DNA VECTORS OBTAINABLE FROM CELL-FREE SYNTHESIS AND PROCESS FOR OBTAINING CEDNA VECTORSJuly 2020February 2025Allow5521NoNo
16783148GENE THERAPY SYSTEMS AND RELATED METHODS FOR TREATMENT OF HEARING LOSSFebruary 2020April 2025Allow6021YesNo
16619898ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTIONDecember 2019April 2025Allow6041YesNo
16616302Genetic ConstructNovember 2019February 2025Allow6041YesNo
16658663GENE THERAPY TARGETING THE NEONATAL FORM OF NAV1.5 FOR TREATING CANCEROctober 2019February 2025Abandon6031NoNo
16580996METHOD AND COMPOSITION FOR ENDOGENOUS PRODUCTION OF CONSTITUTIVELY ACTIVATED RECEPTORS, AND RECEPTORS WITH BROADER BINDING RANGES OR HIGHER AFFINITY THAN NATIVE RECEPTORSSeptember 2019November 2024Abandon6051NoNo
16534667METHODS TO MODULATE PROTEIN TRANSLATION EFFICIENCYAugust 2019June 2025Allow6041YesNo
16480541EXPRESSION VECTOR FOR CHOLESTEROL 24-HYDROLASE IN THERAPY OF POLYGLUTAMINE REPEAT SPINOCEREBELLAR ATAXIASJuly 2019July 2024Allow5930YesYes
16451906COMPOSITIONS AND METHODS FOR INHIBITION OF LINEAGE SPECIFIC ANTIGENSJune 2019February 2024Abandon5641NoYes
16318745THERAPEUTIC APPLICATIONS OF CPF1-BASED GENOME EDITINGJanuary 2019October 2022Allow4531YesNo
15774491IMPROVED PARAMYXOVIRUS VECTORJanuary 2019December 2024Allow6051YesYes
16310207TRUNCATED DYSFERLIN FOR TREATMENT OF DYSFERLINOPATHYDecember 2018December 2024Allow6061YesNo
16085553GENERATION OF MIDBRAIN-SPECIFIC ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLSSeptember 2018May 2025Allow6061YesNo
15999281COMPOSITIONS AND METHODS OF USING STAT1/3 INHIBITORS WITH ONCOLYTIC HERPES VIRUSAugust 2018December 2024Abandon6051NoNo
16072674GENETIC, DEVELOPMENTAL AND MICRO-ENVIRONMENTAL PROGRAMS IN IDH-MUTANT GLIOMAS, COMPOSITIONS OF MATTER AND METHODS OF USE THEREOFJuly 2018February 2025Abandon6021NoNo
16068929DIFFERENTIATION INDUCTION FROM HUMAN PLURIPOTENT STEM CELLS INTO HYPOTHALAMIC NEURONSJuly 2018April 2025Allow6071YesNo
16067761METHOD FOR PREPARING 3D CARTILAGE ORGANOID BLOCKJuly 2018September 2023Abandon6060YesNo
16065201MEDICAMENT FOR TREATING CEREBRAL INFARCTIONJune 2018April 2025Abandon6080YesNo
15996337COMPOSITIONS AND METHODS FOR IMPROVING IMMUNOTHERAPYJune 2018April 2025Allow6062YesNo
15769873CELL BANK OF HIGH CONCENTRATION ADIPOSE-DERIVED STEM CELL COMPOSITION AND RELATED METHODSApril 2018June 2025Allow6061YesNo
15769615SYNTHETIC COMBINATORIAL AAV3 CAPSID LIBRARYApril 2018July 2024Allow6042YesNo
15950383METHOD FOR SUPPRESSION OF OR PROTECTION FROM ISCHEMIA/REPERFUSION INJURY OF ORGANS FOR TRANSPLANTATIONApril 2018May 2025Abandon6051NoNo
15764275METHODS AND ARTICLES OF MANUFACTURE FOR THE TREATMENT OF ANIMALSMarch 2018December 2024Abandon6071YesYes
15934029MACRO TISSUE EXPLANT, METHODS AND USES THEREFORMarch 2018January 2025Abandon6061YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner NICOL, ALEXANDER W.

Strategic Value of Filing an Appeal

Total Appeal Filings
3
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
3
(100.0%)
Filing Benefit Percentile
0.3%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner NICOL, ALEXANDER W - Prosecution Strategy Guide

Executive Summary

Examiner NICOL, ALEXANDER W works in Art Unit 1634 and has examined 40 patent applications in our dataset. With an allowance rate of 55.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 10000 months.

Allowance Patterns

Examiner NICOL, ALEXANDER W's allowance rate of 55.0% places them in the 10% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by NICOL, ALEXANDER W receive 3.55 office actions before reaching final disposition. This places the examiner in the 99% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by NICOL, ALEXANDER W is 10000 months. This places the examiner in the 0% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +50.0% benefit to allowance rate for applications examined by NICOL, ALEXANDER W. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 16.8% of applications are subsequently allowed. This success rate is in the 8% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 10.0% of cases where such amendments are filed. This entry rate is in the 5% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 70.6% are granted (fully or in part). This grant rate is in the 87% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.